Trial · NCT04930328
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from pre-Oxbryta treatment period in Hemoglobin (Hb) | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Change from pre-Oxbryta treatment period in percent Reticulocytes | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Change from pre-Oxbryta treatment period in Absolute Reticulocytes | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Change from pre-Oxbryta treatment period in Bilirubin | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Incidence of significant SCD-related clinical events | 1 year before and 1 year after the first dose of Oxbryta | Such as vaso-occlusive crisis (VOC), acute chest syndrome (ACS), priapism, cerebral infarcts, transient ischemic attack (TIA), leg ulcers, and measures of cardiac function and pulmonary hypertension (PH) |
| Primary | Change from pre-Oxbryta treatment period in incidence of unplanned clinic visits | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Change from pre-Oxbryta treatment period in incidence of emergency department (ED) visits | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Change from pre-Oxbryta treatment period in incidence of hospitalizations (including total length of stay and time in intensive care unit [ICU], if applicable) | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Change from pre-Oxbryta treatment period in incidence of red blood cell transfusions | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Incidence and severity of serious adverse events (SAEs) | 1 year before and 1 year after the first dose of Oxbryta | |
| Primary | Incidence and severity of adverse events (AEs) of interest | 1 year before and 1 year after the first dose of Oxbryta | Such as Rash, Diarrhea, Headache, AEs leading to Oxbryta dose modification or discontinuation |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04930328/registered